Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis

Background and Aims: Glucagon-like peptide-1(GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists are increasingly used for metabolic disease, but their safety profile in patients with chronic pancreatitis (CP) remains uncertain. We compared several gastrointestinal, cardio, renal and metabolic outcomes in patients with CP exposed to dulaglutide, semaglutide, or tirzepatide versus propensity-matched unexposed controls. Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX federated real-world data platform. Adults with CP were classified by recorded exposure to dulaglutide, semaglutide, or tirzepatide versus no recorded exposure to those drugs. Risk analyses and Kaplan-Meier time-to-event analyses were done. Results: After matching, median follow-up was 588 (IQR 831) versus 879 (IQR 807), respectively. Nausea/vomiting occurred in 656/4,938 (risk 0.133) versus 1,099/5,585 (risk 0.197), with risk ratio (RR) 0.675 (95%CI: 0.618-0.738) and hazard ratio (HR) 0.710 (95%CI: 0.645-0.783). Bowel obstruction/ileus occurred in 241/9,103 (risk 0.026) versus 466/8,949 (risk 0.052), with RR=0.508 (95%CI: 0.436-0.592) and HR=0.556 (95%CI: 0.476-0.649). Upper gastrointestinal bleeding occurred in 355/8,536 (risk 0.042) versus 608/8,657 (risk 0.070), with RR=0.592 (95%CI: 0.521-0.673) and HR=0.659 (95%CI: 0.578-0.751). Biliary/procedural outcomes were lower, including cholecystectomy (risk 0.023 vs 0.049; HR=0.486, 95%CI: 0.412-0.572) and ERCP (risk 0.026 vs 0.064; HR=0.420, 95%CI: 0.362-0.488). Recurrent acute pancreatitis occurred in 329/5,639 exposed patients (risk 0.058) versus 579/5,499 controls (risk 0.105), with HR=0.584 (95%CI: 0.510-0.669). Additional associations included lower insulin initiation (risk 0.178 vs 0.269; HR=0.731, 95%CI: 0.658-0.812), heart failure (risk 0.061 vs 0.101; HR=0.687, 95%CI: 0.613-0.770), myocardial infarction (risk 0.039 vs 0.054; HR=0.818, 95%CI: 0.712-0.939 and acute kidney injury (risk 0.086 vs 0.150; HR=0.643, 95%CI: 0.580-0.712), malnutrition (risk 0.049 vs 0.107; HR=0.491, 95%CI: 0.438-0.550). Conclusions: Exposure to dulaglutide, semaglutide, or tirzepatide was associated with lower recorded risks across several gastrointestinal, cardio, renal and metabolic outcome domains. These findings should be interpreted with caution, and further prospective studies are required to confirm the same.

Authors

Institutions

Publication Details

Journal
Journal of Gastrointestinal and Liver Diseases
Published
2026-11-21
DOI
https://doi.org/10.15403/jgld-6964
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis

Arkadeep Dhali, Fayaz Khan, Rick Maity
Journal of Gastrointestinal and Liver Diseases
Diabetes Treatment and Management
article

Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis

Arkadeep Dhali, Fayaz Khan, Rick Maity
article en

Abstract

Background and Aims: Glucagon-like peptide-1(GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists are increasingly used for metabolic disease, but their safety profile in patients with chronic pancreatitis (CP) remains uncertain. We compared several gastrointestinal, cardio, renal and metabolic outcomes in patients with CP exposed to dulaglutide, semaglutide, or tirzepatide versus propensity-matched unexposed controls. Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX federated real-world data platform. Adults with CP were classified by recorded exposure to dulaglutide, semaglutide, or tirzepatide versus no recorded exposure to those drugs. Risk analyses and Kaplan-Meier time-to-event analyses were done. Results: After matching, median follow-up was 588 (IQR 831) versus 879 (IQR 807), respectively. Nausea/vomiting occurred in 656/4,938 (risk 0.133) versus 1,099/5,585 (risk 0.197), with risk ratio (RR) 0.675 (95%CI: 0.618-0.738) and hazard ratio (HR) 0.710 (95%CI: 0.645-0.783). Bowel obstruction/ileus occurred in 241/9,103 (risk 0.026) versus 466/8,949 (risk 0.052), with RR=0.508 (95%CI: 0.436-0.592) and HR=0.556 (95%CI: 0.476-0.649). Upper gastrointestinal bleeding occurred in 355/8,536 (risk 0.042) versus 608/8,657 (risk 0.070), with RR=0.592 (95%CI: 0.521-0.673) and HR=0.659 (95%CI: 0.578-0.751). Biliary/procedural outcomes were lower, including cholecystectomy (risk 0.023 vs 0.049; HR=0.486, 95%CI: 0.412-0.572) and ERCP (risk 0.026 vs 0.064; HR=0.420, 95%CI: 0.362-0.488). Recurrent acute pancreatitis occurred in 329/5,639 exposed patients (risk 0.058) versus 579/5,499 controls (risk 0.105), with HR=0.584 (95%CI: 0.510-0.669). Additional associations included lower insulin initiation (risk 0.178 vs 0.269; HR=0.731, 95%CI: 0.658-0.812), heart failure (risk 0.061 vs 0.101; HR=0.687, 95%CI: 0.613-0.770), myocardial infarction (risk 0.039 vs 0.054; HR=0.818, 95%CI: 0.712-0.939 and acute kidney injury (risk 0.086 vs 0.150; HR=0.643, 95%CI: 0.580-0.712), malnutrition (risk 0.049 vs 0.107; HR=0.491, 95%CI: 0.438-0.550). Conclusions: Exposure to dulaglutide, semaglutide, or tirzepatide was associated with lower recorded risks across several gastrointestinal, cardio, renal and metabolic outcome domains. These findings should be interpreted with caution, and further prospective studies are required to confirm the same.

Journal of Gastrointestinal and Liver Diseases
Roswell Park Comprehensive Cancer Center (US), Indian Institute of Technology Kharagpur (IN), Sheffield Teaching Hospitals NHS Foundation Trust (GB)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon